Back to top
more

Penumbra (PEN)

(Delayed Data from NYSE)

$233.30 USD

233.30
525,994

+4.43 (1.94%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $233.26 -0.04 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Tandem Diabetes Care, Inc. (TNDM) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of -17.39% and 3.94%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

PROCEPT BioRobotics Corporation (PRCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Retain Penumbra (PEN) Stock for Now

by Zacks Equity Research

Investors remain optimistic for Penumbra (PEN), backed by the strength of its portfolio.

Penumbra (PEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Penumbra (PEN) Rides on Vascular Arm Strength Amid FX Woes

by Zacks Equity Research

Penumbra's (PEN) Vascular business is demonstrating strong growth, banking on a rapid increase in sales of vascular thrombectomy products in the United States.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why You Should Retain Centene (CNC) Stock For Now

by Zacks Equity Research

Centene (CNC) remains well-poised for growth on the back of overall membership growth, acquisitions, business streamlining efforts and a growing cash balance.

Moumi Mondal headshot

5 Impressive MedTech Industry Growth Stocks to Buy for 2024

by Moumi Mondal

Stocks such as HAE, PEN, EXAS, PODD and CAH are set to garner remarkable growth for investors.

Integer Holdings Corporation (ITGR) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Integer (ITGR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Here's Why You Should Invest in Insulet (PODD) Stock for Now

by Zacks Equity Research

Investors are optimistic about Insulet (PODD), led by the strong adoption of Omnipod 5 and its strong solvency position.

Why You Should Invest in Encompass Health (EHC) Stock for Now

by Zacks Equity Research

Encompass Health (EHC) is well-poised for growth on the back of growing revenues, an aging U.S. population, joint ventures and solid cash reserves.

5 MedTech Stocks Poised to Continue Their Winning Streaks in 2024

by Zacks Equity Research

Stocks like DexCom Inc. (DXCM), Integer Holdings (ITGR), Penumbra (PEN), Haemonetics (HAE), Health Equity (HAE) and are likely to continue their strong performance in 2024.

Penumbra (PEN) Stock Up 16.2% YTD: Will the Rally Continue?

by Zacks Equity Research

Investors are optimistic about Penumbra (PEN), driven by growth in the vascular segments and upbeat guidance.

Here's Why You Should Invest in Penumbra (PEN) Stock Now

by Zacks Equity Research

Investors are optimistic about Penumbra (PEN), which is led by growth in vascular and neuro businesses.

Acadia Healthcare (ACHC) Opens Facility to Serve California

by Zacks Equity Research

Acadia Healthcare (ACHC) conducts a ribbon-cutting ceremony for its Indio-based acute care facility, which aims to cater to the dire need for high-quality behavioral healthcare services in the region.

Why Is OPKO Health (OPK) Up 18.7% Since Last Earnings Report?

by Zacks Equity Research

OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Wall Street Analysts See a 26.89% Upside in Penumbra (PEN): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for Penumbra (PEN) points to a 26.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Penumbra (PEN) Enrolls First Patient in Landmark STORM-PE Trial

by Zacks Equity Research

Penumbra (PEN) achieves an important milestone by enrolling the first patient in STORM-PE RCT.

Penumbra's (PEN) Expansion Moves, New Launches Aid Growth

by Zacks Equity Research

Penumbra (PEN) expects to materially increase both revenues and profitability of the international business in the next three years and beyond.

Here's Why Investors Should Hold Encompass Health (EHC) Now

by Zacks Equity Research

Encompass Health (EHC) remains well-poised for growth on the back of an active expansion strategy and sufficient cash-generating abilities.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why You Should Retain Penumbra (PEN) Stock for Now

by Zacks Equity Research

Investors are optimistic about Penumbra (PEN) on strong vascular and neuro businesses growth and upbeat guidance.

Wall Street Analysts Think Penumbra (PEN) Could Surge 37.71%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for Penumbra (PEN) points to a 37.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Down -11.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Penumbra (PEN)

by Zacks Equity Research

Penumbra (PEN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Penumbra (PEN) Q3 Earnings Top Estimates, Margins Increase

by Zacks Equity Research

Penumbra's (PEN) vascular and neuro product categories continue to show encouraging growth trends.